For over a decade, to show that a claim term is invalid as indefinite under 35 U.S.C. §112, ¶2, the Federal Circuit has required that such terms be “not amenable to construction” or “insolubly ambiguous.” The Supreme Court in Nautilus, Inc. v. Biosig Instruments, Inc. has rejected that standard on the grounds that it tolerates too much imprecision. Under the new standard, a claim term is indefinite if it, instead, fails to define “the scope of the invention with reasonable certainty.”
The patent at issue, assigned to Biosig Instruments, Inc. (“Biosig”), involves a heart-rate monitor used with exercise equipment. Prior heart-rate monitors, the patent asserts, were often inaccurate in measuring the electrical signals accompanying each heartbeat (electrocardiograph or ECG signals) because of the presence of other electrical signals (electromyogram or EMG signals) generated by the user’s skeletal muscles. The invention claims to improve on prior art by detecting and processing ECG signals in a way that filters out the EMG interference.
Claim 1 of the patent, which contains the limitations critical to the case, recites a “heart rate monitor for use by a user in association with exercise apparatus and/or exercise procedures.” The claim comprises, among other elements, a cylindrical bar with a “live” electrode and a “common” electrode “mounted . . . in spaced relationship with each other.” Biosig filed the underlying patent infringement suit, alleging that Nautilus, Inc. (“Nautilus”) infringed on its patented claims by selling exercise machines containing Biosig’s patented technology.